Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.23.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2023
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2022

378,897

$

26.15

Granted

958,800

2.25

Forfeited

(4,350)

26.29

Vested

(82,275)

26.73

Non-vested at March 31, 2023

1,251,072

$

7.79

Summary of restricted stock units activity

    

    

Weighted Average

Number of

Grant Date Fair

Shares

Value

Non-vested at December 31, 2022

 

85,000

$

10.50

Granted

 

577,384

 

2.25

Vested

(42,500)

10.50

Non-vested at March 31, 2023

 

619,884

$

2.82

Summary of stock option award activity

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2022

27,000

$

31.35

6.44

Outstanding as of March 31, 2023

27,000

$

31.35

6.19

Vested and exercisable as of March 31, 2023

17,500

$

23.88

6.63

Summary of warrant activities

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2022

4,357,597

$

3.37

3.26

Granted

3,191,430

4.65

Exercised

(1,032,816)

Outstanding as of March 31, 2023

6,516,211

$

4.53

3.01

Summary of stock-based compensation expense

For the three months ended March 31, 

    

2023

    

2022

Research and development

$

390

$

247

General and administrative

 

579

 

528

Total stock-based compensation expense

$

969

$

775